Page last updated: 2024-09-03

rasagiline and Parkinsonian Disorders

rasagiline has been researched along with Parkinsonian Disorders in 17 studies

Research

Studies (17)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (23.53)	29.6817
2010's	10 (58.82)	24.3611
2020's	3 (17.65)	2.80

Authors

Authors	Studies
Finberg, JPM	1
Bali, NR; Salve, PS	1
Arawaka, S; Kato, T; Nakamura, Y; Sasaki, A; Sato, H; Shigekiyo, T; Takahata, K; Tsunekawa, H	1
Bhandari, R; Kanwar, N; Kuhad, A; Sinha, VR	1
Galpern, WR	1
Barone, P; Eyal, E; Fitzer-Attas, CJ; Giladi, N; Gilman, S; Low, PA; Poewe, W; Rascol, O; Sampaio, C; Seppi, K; Wenning, GK	1
Carceller, M; Kulisevsky, J; Martínez-Horta, S; Pagonabarraga, J; Pérez-Pérez, J	1
Badrinarayanan, S; Boivin, L; Bousquet, M; Chabrat, A; Charest, J; Cicchetti, F; Cisbani, G; Drouin-Ouellet, J; Gibrat, C; Lagacé, M; Lavallée-Bourget, MH; Lebel, M; Lévesque, M; Saint-Pierre, M	1
Canning, SD; Wang, XP; Zhang, LL	1
Abler, V; Krismer, F; Papapetropoulos, S; Poewe, W; Seppi, K; Wenning, GK	1
Amit, T; Kalfon, L; Mandel, SA; Reznichenko, L; Youdim, MB	1
Amit, T; Bar-Am, O; Prosolovich, K; Weinreb, O; Youdim, MB	1
Barcia, E; Fernández, M; Fernández-Carballido, A; Negro, S; Slowing, K	1
Dallemagne, P; Demotes-Mainard, J; Guillon, J; Hébert, G; Jarry, C; Léger, JM; Lisowski, V; Rault, S; Thé, C; Vidaillac, C	1
Armentero, MT; Blandini, F; Blaugrund, E; Fancellu, R; Nappi, G	1
Bhat, V; Weiner, WJ	1
Breithaupt, W; Gerlach, M; Götz, ME; Kupsch, A; Oertel, WH; Riederer, P; Sautter, J; Schwarz, J; Youdim, MB	1

Reviews

2 review(s) available for rasagiline and Parkinsonian Disorders

Article	Year
Freezing of Gait in Parkinsonism and its Potential Drug Treatment. Current neuropharmacology, 2016, Volume: 14, Issue:4 Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Botulinum Toxins; Droxidopa; Gait Disorders, Neurologic; Humans; Indans; Levodopa; Methylphenidate; Middle Aged; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Selegiline; Treatment Outcome	2016
Parkinson's disease. Diagnosis and the initiation of therapy. Minerva medica, 2005, Volume: 96, Issue:3 Topics: Antioxidants; Diagnosis, Differential; Dopamine Agonists; Humans; Hypokinesia; Indans; Levodopa; Muscle Rigidity; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Selegiline; Tremor	2005

Trials

2 trial(s) available for rasagiline and Parkinsonian Disorders

Article	Year
Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. The Lancet. Neurology, 2015, Volume: 14, Issue:2 Topics: Aged; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Multiple System Atrophy; Neuroprotective Agents; Parkinsonian Disorders; Treatment Outcome	2015
Minimally clinically important decline in the parkinsonian variant of multiple system atrophy. Movement disorders : official journal of the Movement Disorder Society, 2016, Volume: 31, Issue:10 Topics: Aged; Female; Humans; Indans; Male; Middle Aged; Minimal Clinically Important Difference; Multiple System Atrophy; Neuroprotective Agents; Parkinsonian Disorders; Severity of Illness Index	2016

Other Studies

13 other study(ies) available for rasagiline and Parkinsonian Disorders

Article	Year
The discovery and development of rasagiline as a new anti-Parkinson medication. Journal of neural transmission (Vienna, Austria : 1996), 2020, Volume: 127, Issue:2 Topics: Animals; History, 20th Century; History, 21st Century; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinsonian Disorders	2020
Impact of rasagiline nanoparticles on brain targeting efficiency via gellan gum based transdermal patch: A nanotheranostic perspective for Parkinsonism. International journal of biological macromolecules, 2020, Dec-01, Volume: 164 Topics: Administration, Cutaneous; Administration, Oral; Animals; Behavior, Animal; Brain; Catalepsy; Diffusion; Indans; Kinetics; Male; Nanoparticles; Parkinsonian Disorders; Particle Size; Polyesters; Polysaccharides, Bacterial; Rats; Rats, Wistar; Skin; Solvents; Tensile Strength; Theranostic Nanomedicine; Tissue Distribution; Transdermal Patch	2020
Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion The Journal of neuroscience : the official journal of the Society for Neuroscience, 2021, 09-01, Volume: 41, Issue:35 Topics: alpha-Synuclein; Animals; ATP-Binding Cassette Transporters; Cell Death; Cell Line, Tumor; Corpus Striatum; Culture Media, Conditioned; Dopaminergic Neurons; Gene Knockdown Techniques; Genetic Vectors; Humans; Indans; Injections; Lysosomes; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Mutation, Missense; Neuroblastoma; Parkinsonian Disorders; Protein Aggregation, Pathological; Protein Transport; Rats; Rats, Sprague-Dawley; Recombinant Proteins; RNA, Small Interfering; Selegiline; Substantia Nigra	2021
Polycaprolactone-based neurotherapeutic delivery of rasagiline targeting behavioral and biochemical deficits in Parkinson's disease. Drug delivery and translational research, 2019, Volume: 9, Issue:5 Topics: Animals; Behavior, Animal; Brain; Delayed-Action Preparations; Drug Liberation; Glutathione; Hydrogen-Ion Concentration; Indans; Injections, Subcutaneous; Lipid Peroxidation; Locomotion; Male; Microspheres; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinsonian Disorders; Polyesters; Rats, Sprague-Dawley; Rotenone; Superoxide Dismutase	2019
Clinical trials for multiple system atrophy. The Lancet. Neurology, 2015, Volume: 14, Issue:2 Topics: Female; Humans; Indans; Male; Multiple System Atrophy; Neuroprotective Agents; Parkinsonian Disorders	2015
Rasagiline for the treatment of parkinsonism in Huntington's disease. Parkinsonism & related disorders, 2015, Volume: 21, Issue:3 Topics: Adult; Aged; Female; Humans; Huntington Disease; Indans; Neuroprotective Agents; Parkinsonian Disorders	2015
Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease. Neurobiology of disease, 2015, Volume: 82 Topics: Animals; Antiparkinson Agents; Astrocytes; Cell Line; Cells, Cultured; Corpus Striatum; Cystamine; Cysteamine; Disease Models, Animal; Dopaminergic Neurons; Indans; Lipopolysaccharides; Male; Mice, Inbred C57BL; Neurites; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders	2015
Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism. Neuro-degenerative diseases, 2010, Volume: 7, Issue:4 Topics: Animals; Antioxidants; Catechin; Cell Line; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Indans; Male; Mice; Mice, Inbred C57BL; Neural Pathways; Neuroprotective Agents; Parkinsonian Disorders; Recovery of Function; Substantia Nigra; Treatment Outcome	2010
Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's disease? Antioxidants & redox signaling, 2011, Mar-01, Volume: 14, Issue:5 Topics: Acetylcysteine; Animals; Catalase; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Humans; Hydrogen Peroxide; Indans; Male; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; PC12 Cells; Rats; Rats, Sprague-Dawley	2011
An effective novel delivery strategy of rasagiline for Parkinson's disease. International journal of pharmaceutics, 2011, Oct-31, Volume: 419, Issue:1-2 Topics: Animals; Antiparkinson Agents; Brain; Delayed-Action Preparations; Disease Models, Animal; Fluorodeoxyglucose F18; Indans; Injections, Intraperitoneal; Lactic Acid; Male; Microspheres; Multimodal Imaging; Parkinsonian Disorders; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Positron-Emission Tomography; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Rotenone; Tomography, X-Ray Computed	2011
Synthesis and initial results for MAO-B inhibition by new N-propargyl-3-pyrrol-1-ylindanamine derivatives, analogues of rasagiline. Journal of enzyme inhibition and medicinal chemistry, 2003, Volume: 18, Issue:2 Topics: Animals; Disease Models, Animal; Indans; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Pyrroles; Stereoisomerism; Structure-Activity Relationship	2003
Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Experimental neurology, 2004, Volume: 187, Issue:2 Topics: Animals; Cell Count; Disease Models, Animal; Dose-Response Relationship, Drug; Indans; Male; Monoamine Oxidase Inhibitors; Motor Activity; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra; Treatment Outcome; Tyrosine 3-Monooxygenase	2004
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. Journal of neural transmission (Vienna, Austria : 1996), 2001, Volume: 108, Issue:8-9 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Callithrix; Disease Models, Animal; Dopamine; Dopamine Agents; Female; Immunohistochemistry; Indans; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motor Activity; Neostriatum; Neurons; Norepinephrine; Parkinsonian Disorders; Selegiline; Serotonin; Substantia Nigra	2001